Citations

Showing 10 of 108094 citations.

A Case of Atypical Alzheimer’s Disease With Clinical Manifestation That Straddled the Boundary Between Primary Progressive Aphasia and Posterior Cortical Atrophy
Chandregowda, Adithya , Pham, Nha Trang Thu, Lowe, Val J. , Josephs, Keith A. , Whitwell, Jennifer L. , Clark, Heather M. , Machulda, Mary M.

Mayo Clinic

The Neurologist | August 18, 2022 | Volume: 28 | Issue: 3 | Pages: 195-197

10.1097/nrl.0000000000000458 | PMID 35981305 Get It

Introduction: In the context of Alzheimer’s disease phenotypes, patients may present with symptoms and signs that do not exclusively fit into one of the existing phenotypic categories, which often delays timely diagnosis and initiation of services to optimize patient awareness and coping. Case Report: A 74-year-old woman presented with the complaint of progressive word-finding difficulty, raising our suspicion for primary progressive aphasia. Clinical evaluations, however, also revealed emerging cortical visual deficits consistent with posterior cortical atrophy. During evaluation 1 year later, Gerstmann syndrome was evident. Her in vivo neuroimaging was positive for beta-amyloid and tau biomarkers of Alzheimer’s disease pathology. Conclusion: In addition to contributing to the literature on the heterogeneity of the clinical manifestations of Alzheimer’s disease, this report highlights that a breakdown in the visual-lexical interface can account for anomia in posterior cortical atrophy at least in some cases. Other relevant clinical insights pertinent to this case are discussed.
Faculty Opinions recommendation of Continuous wound infusion combined with intrathecal morphine for analgesia after Cesarean delivery compared with intrathecal morphine or continuous wound infusion alone.
Sviggum, Hans P.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 18, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742005335.793594799 Get It

Size Frequency Distributions, Fracture Patterns, and Reactive Surface Area of Shock Wave Lithotripsy-Derived Particles: A GeoBioMed Perspective on Kidney Stone Recurrence
Todorov, Lauren G. , Krambeck, Amy E. , Fouke, Bruce W. , Sivaguru, Mayandi , Lee, Matthew , Lieske, John C.

Mayo Clinic

No container title available | August 18, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1887469/v1 Get It

Abstract Shock wave lithotripsy (SWL) is an effective and commonly applied clinical treatment for human kidney stones. Yet the success of SWL is counterbalanced by the risk of retained fragments causing recurrent stone formation, which may require retreatment. This study has applied GeoBioMed experimental and analytical approaches to determine the size frequency distribution, fracture patterns, and reactive surface area of SWL-derived particles within the context of their original crystal growth structure (crystalline architecture) as revealed by confocal autofluorescence (CAF) and super-resolution autofluorescence (SRAF) microscopy. Multiple calcium oxalate (CaOx) stones were removed from a Mayo Clinic patient using standard percutaneous nephrolithotomy (PCNL) and shock pulse lithotripsy (SPL). This produced approximately 4-12mm-diameter PCNL-derived fragments that were experimentally treated ex vivo with SWL to form hundreds of smaller particles. Fractures propagated through the crystalline architecture of PCNL-derived fragments in a variety of geometric orientations to form rectangular, pointed, concentrically spalled, and irregular SWL-derived particles. Size frequency distributions ranged from fine silt (4-8mm) to very fine pebbles (2-4mm), according to the Wentworth grain size scale, with a mean size of fine sand (125-250mm). Importantly, these SWL-derived particles are smaller than the 3-4mm-diameter detection limit of clinical microcomputed tomography (micro-CT) techniques and can be retained on internal kidney membrane surfaces. This creates clinically undetectable crystallization seed points with extremely high reactive surface areas, which dramatically enhance the multiple events of crystallization and dissolution (diagenetic phase transitions) that may lead to the high rates of CaOx kidney stone recurrence after SWL treatment.
Generation of chromosome 1p/19q co-deletion by CRISPR/Cas9-guided genomic editing
Zhang, Xiaoxia , Wang, Huafeng , Friedman, Gregory K. , Ding, Qiang , Yu, Xi, Han, Xiaosi , Zhao, Rui , Zhao, Rui , Li, Chao , Liu, Zhong Y. , Zhao, Xinyang , Li, Hu , Kim, Kitai , Nabors, Burt

Mayo Clinic

Neuro-Oncology Advances | August 18, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac131 | PMID 36225650 Get It

Abstract Background Chromosomal translocation has been detected in many human cancers including gliomas and is considered a driving force in tumorigenesis. Co-deletion of chromosome arms 1p and 19q is a hallmark for oligodendrogliomas. On the molecular level, 1p/19q co-deletion results from t(1;19)(q10;p10), which leads to the concomitant formation of a hybrid chromosome containing the 1q and 19p arms. A method to generate 1p/19q co-deletion is lacking, which hinders the investigation of how 1p/19q co-deletion contributes to gliomagenesis. Methods We hypothesized that chromosomal translocation, such as t(1;19)(q10;p10) resulting in the 1p/19q co-deletion, may be induced by simultaneously introducing DNA double-strand breaks (DSBs) into chromosomes 1p and 19q using CRISPR/Cas9. We developed a CRISPR/Cas9-based strategy to induce t(1;19)(q10;p10) and droplet digital PCR (ddPCR) assays to detect the hybrid 1q/19p and 1p/19q chromosomes. Results After translocation induction, we detected both 1p/19q and 1q/19p hybrid chromosomes by PCR amplification of the junction regions in HEK 293T, and U-251 and LN-229 glioblastoma cells. Sequencing analyses of the PCR products confirmed DNA sequences matching both chromosomes 1 and 19. Furthermore, the 1p/19q hybrid chromosome was rapidly lost in all tested cell lines. The 1q/19p hybrid chromosome also become undetectable over time likely due to cell survival disadvantage. Conclusion We demonstrated that t(1;19)(q10;p10) may be induced by CRISPR/Cas9-mediated genomic editing. This method represents an important step toward engineering the 1p/19q co-deletion to model oligodendrogliomas. This method may also be generalizable to engineering other cancer-relevant translocations, which may facilitate the understanding of translocation roles in cancer progression.
Outcomes of patients with acute liver failure listed for liver transplantation: A multicenter prospective cohort analysis
Karvellas, Constantine , Leventhal, Thomas M. , Rakela, Jorge , Durkalski, Valerie, Reddy, K. Rajender , Stravitz, R. Todd , Lee, William M. , Parekh, Justin , Karvellas, Constantine , Rakela, Jorge , Rajender Reddy, K , Lee, William M , Zhang, Jingwen , Fontana, Robert J. , Lake, John R.

Mayo Clinic

Liver Transplantation | August 18, 2022 | Volume: 29 | Issue: 3 | Pages: 318-330

10.1002/lt.26563 | PMID 35980605 Get It

Liver transplantation (LT) is a life‐saving treatment for patients with acute liver failure (ALF). Currently, there are few detailed data regarding long‐term outcomes after LT for ALF. We combined prospective data from the Acute Liver Failure Study Group (ALFSG) Registry with those of the Scientific Registry of Transplant Recipients (SRTR) to assess outcomes among consecutive patients with ALF listed for LT. Cohort analysis of detailed pretransplantation data for patients listed for LT for ALF in the ALFSG Registry between January 1998 and October 2018 matched with transplantation‐related data from the SRTR. Primary outcomes were 1‐ and 3‐year post‐LT patient survival. Secondary outcome was receipt of LT; independent associations with successful receipt of LT were determined using multivariable logistic regression. Of 624 patients with ALF listed for LT, 398 (64%) underwent LT, 100 (16%) died without LT, and 126 (20%) recovered spontaneously. Among LT recipients, etiologies included seronegative/indeterminate (22%), drug‐induced liver injury (18%), acetaminophen overdose (APAP; 16%), and viral hepatitis (15%). The 1‐ and 3‐year post‐LT patient survival rates were 91% and 90%, respectively. Comparing those dying on the waiting list versus with those who received LT, the former had more severe multiorgan failure, reflected by increased vasopressor use (65% vs. 22%), mechanical ventilation (84% vs. 57%), and renal replacement therapy (57% vs. 30%; p < 0.0001 for all). After adjusting for relevant covariates, age (adjusted odds ratio [aOR] 1.02, 95% confidence interval [CI] 1.00–1.04), APAP etiology (aOR 2.72, 95% CI 1.42–5.23), requirement for vasopressors (aOR 4.19, 95% CI 2.44–7.20), Grade III/IV hepatic encephalopathy (aOR 2.47, 95% CI 1.29–4.72), and Model for End‐Stage Liver Disease (MELD) scores (aOR 1.05, 95% CI 1.02–1.09; p < 0.05 for all) were independently associated with death without receipt of LT. Post‐LT outcomes for ALF are excellent in this cohort of very ill patients. The development of multiorgan failure while on the transplantation list and APAP ALF etiology were associated with a lower likelihood of successful receipt of LT.
Acceptability of a Brief, Intensive Adolescent Obesity Intervention With Wellness Coaching
Biggs, Bridget K. , Vickers, Kristin S. , Hathaway, Julie, Hofschulte, Deanna R., Clark, Matthew M. , Mapes, Melissa D., Murad, Angela L. , Peterson, Nolan W., Prigge, Bradly, Kumar, Seema , Cunningham, Megan, Hensrud, Donald D. , Biggs, Bridget K

Mayo Clinic

Clinical Practice in Pediatric Psychology | August 18, 2022 | Volume: 11 | Issue: 2 | Pages: 206-216

10.1037/cpp0000449 Get It

Objective: This report describes data regarding the acceptability of delivering a family-based behavioral lifestyle intervention for adolescent obesity in a brief, intensive onsite program (initial 3 sequential days + 1 follow-up day) combined with telephonic wellness coaching (WC). Methods: Four cohorts consisting of 7 adolescents aged 15–17 years (self-identifying as 4 male, 2 female, 1 transgender male; 6 White, 1 African American and White) and thirteen parents participated in a new clinical intervention consisting of 3 days onsite programming, 3-months telephonic wellness coaching, and 1 day onsite follow up. Enrollment, attendance, and retention were recorded. Participants provided quantitative and qualitative feedback regarding acceptability of the program during postintervention interviews. Results: Of 11 families invited, 8 enrolled. Seven families participated, with 1 family lost to follow up. Adolescents completed an average 5.6/9 planned WC sessions. Adolescents rated the program positively overall and liked experiential sessions best. However, participants reported the onsite program was too long, they encountered barriers to sustained engagement during wellness coaching follow up, and parents desired greater guidance and structure for their involvement. Conclusions: Combining in-person sessions with telephonic wellness coaching was acceptable to participants, but intervention refinement is needed. Future program development and research investigating hybrid models should consist of briefer in-person sessions, emphasize skill practice, and include ongoing guidance to parents to provide developmentally appropriate support. Implications for Impact Statement This new clinical program evaluation found that extending onsite family-based behavioral lifestyle intervention for adolescent obesity with telephonic wellness coaching was acceptable to participants, but that program refinement is needed. Feedback highlighted the importance of keeping onsite sessions brief, engaging adolescents with hands-on skill practice, and providing ongoing guidance to parents to support sustained adolescent engagement in behavior change.
Guidelines of the International Headache Society for Controlled Clinical Trials in Cluster Headache
Schoenen, Jean , Snoer, Agneta, Brandt, Roemer B. , Fronczek, Rolf , Wei, Diana Y. , Chung, Chin‐Sang , Diener, Hans‐Christoph , Goadsby, Peter J. , Matharu, Manjit , McGinley, James S., Tepper, Stewart J. , Brandt, Roemer W, Tassorelli, Cristina , Leroux, Élizabeth , Christensen, Marie Deen, Goadsby, Peter J , Matharu, Manjit Singh , May, Arne , Diener, Hans-Christoph , Schoenen, Jean , Dodick, David W. , Fontaine, Denys , May, Arne , Jensen, Rigmor , Ferrari, Michel D. , Terwindt, Gisela M. , Ashina, Messoud , Lipton, Richard B. , Pozo‐Rosich, Patricia , Wang, Shuu‐Jiun , Martini, Daniela, Hoek, Thomas C. van den

Mayo Clinic

Cephalalgia | August 18, 2022 | Volume: 42 | Issue: 14 | Pages: 1450-1466

10.1177/03331024221120266 | PMID 36268950 Get It

In 1995, a committee of the International Headache Society developed and published the first edition of the Guidelines for Controlled Trials of Drugs in Cluster Headache. These have not been revised. With the emergence of new medications, neuromodulation devices and trial designs, an updated version of the International Headache Society Guidelines for Controlled Clinical Trials in Cluster Headache is warranted. Given the scarcity of evidence-based data for cluster headache therapies, the update is largely consensus-based, but takes into account lessons learned from recent trials and demands by patients. It is intended to apply to both drug and neuromodulation treatments, with specific proposals for the latter when needed. The primary objective is to propose a template for designing high quality, state-of-the-art, controlled clinical trials of acute and preventive treatments in episodic and chronic cluster headache. The recommendations should not be regarded as dogma and alternative solutions to particular methodological problems should be explored in the future and scientifically validated.
Abnormal Uterine Bleeding in Perimenopausal Women
Louie, Michelle , Vegunta, Suneela , Louie, Michelle Y

Mayo Clinic

Journal of Women's Health | August 18, 2022 | Volume: 31 | Issue: 8 | Pages: 1084-1086

10.1089/jwh.2022.0273 | PMID 35980245 Get It

The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease
Sundar, Shirin V., Zhou, Julie , Magenheimer, Brenda S., Reif, Gail A. , Georg, Gunda I. , Jakkaraj, Sudhakar , Tash, Joseph S. , Yu, Alan S.L. , Calvet, James P. , Zhou, Julie Xia, Wallace, Darren P , Yu, Alan S L , Li, Xiaogang , Calvet, James P , Wallace, Darren P. , Li, Xiaogang

Mayo Clinic

American Journal of Physiology-Renal Physiology | August 18, 2022 | Volume: 323 | Issue: 4 | Pages: F492-F506

10.1152/ajprenal.00095.2022 | PMID 35979967 Get It

Autosomal dominant polycystic kidney disease (ADPKD) is a renal neoplastic disorder characterized by the formation of large fluid-filled cysts that develop from kidney tubules through abnormal cell proliferation and cyst-filling fluid secretion driven by cAMP-dependent Cl − secretion. This study shows that the lonidamine derivative H2-GMZ inhibits Cl − secretion, cell proliferation, and cyst growth, suggesting that it might have therapeutic value for the treatment of ADPKD.